generalized myasthenia gravis (gMG) is a rare autoimmune disease. Autoimmune diseases occur when the body mistakenly attacks healthy cells, causing damage to certain normal bodily functions. In myasthenia gravis (MG), the immune system damages or destroys receptors that help the body control its muscles, causing muscle weakness and fatigue. There are two types of MG: generalized and ocular.1 Ocular myasthenia gravis, which affects only the muscles that move the eyes and eyelids, is not being evaluated in the Prevail Study. Most people with ocular MG will progress to the generalized form (gMG), which means muscles other than those that move the eyes, such as muscles in the face, neck, arms, legs, and throat, will also be affected. Only patients with gMG will be evaluated in the Prevail Study.
There are several different treatments available for individuals with gMG, but many patients continue to experience symptoms despite these treatments. Therefore, there is an unmet need for more-effective and more-convenient gMG treatments.
By taking part in a study that is evaluating a potential new treatment for gMG, participants in the Prevail Study could make a difference in the lives of others in the gMG community. If you’re interested in this important research, we invite you to click the button below and answer some questions to see if you may qualify for participation.See if you may qualify